Go Pro
→ The window is closing (From American Alternative) (Ad)tc pixel
NASDAQ:RNXT

RenovoRx Q2 2024 Earnings Report

RenovoRx logo
$0.87 -0.01 (-1.14%)
As of 01:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

RenovoRx EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

RenovoRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

RenovoRx Announcement Details

Quarter
Q2 2024
Date
8/13/2024
Time
N/A
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

RenovoRx's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

RenovoRx's Q2 2024 Press ReleasePress Release
(8-K)
RenovoRx's Q2 2024 Quarterly reportQuarterly report
(10-Q)

RenovoRx Earnings Headlines

RenovoRx Stock Short Interest Report | NASDAQ:RNXT | Benzinga
July 7, 2026  |  benzinga.comhttps://www.benzinga.com/quote/RNXT/short-interest
RenovoRx Stockholders Approve Directors and Equity Plan
June 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/renovorx-stockholders-approve-directors-and-equity-plan?utm_source=marketbeat.com&utm_medium=referral
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
July 17 at 1:00 AM  |  American Alternative (Ad)
RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
June 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4917084-renovorx-inc-rnxt-presents-at-iaccess-alpha-virtual-best-ideas-summer-investment-conference
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310469/0/en/renovorx-highlights-peer-reviewed-publication-supporting-intra-arterial-gemcitabine-delivery-via-tamp-in-locally-advanced-pancreatic-cancer.html
Ascendiant Remains a Buy on RenovoRx (RNXT)
June 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RNXT/pressreleases/2303602/ascendiant-remains-a-buy-on-renovorx-rnxt/
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT) is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors. By leveraging a patented catheter design, the system enables localized drug perfusion through arterial infusion, potentially enhancing tumor uptake of chemotherapeutic agents. RenovoRx has also entered strategic collaborations to advance its clinical programs, including licensing arrangements for development and commercialization in select international markets.

Headquartered in Little Silver, New Jersey, RenovoRx conducts its clinical development activities through a network of investigative sites across the United States. The company’s management team comprises seasoned professionals with experience in interventional oncology, medical device development and regulatory affairs. As a Nasdaq-listed entity trading under the symbol RNXT, RenovoRx continues to advance its pipeline toward pivotal studies with the goal of offering new treatment options for patients with limited therapeutic alternatives.

View RenovoRx Profile
Earnings Tools